These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36849900)

  • 1. Association between Cystic Fibrosis exacerbations, lung function, T2 inflammation and microbiological colonization.
    Albon D; Zhang L; Patrie J; Jones M; Li ZG; Noonan E; Borish L
    Allergy Asthma Clin Immunol; 2023 Feb; 19(1):15. PubMed ID: 36849900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series.
    Zhang L; Borish L; Smith A; Somerville L; Albon D
    Allergy Asthma Clin Immunol; 2020; 16():3. PubMed ID: 31921321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
    Walicka-Serzysko K; Sands D
    Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole.
    Nepomuceno IB; Esrig S; Moss RB
    Chest; 1999 Feb; 115(2):364-70. PubMed ID: 10027433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage.
    Erdmann N; Schilling T; Hentschel J; Lehmann T; von Bismarck P; Ankermann T; Duckstein F; Baier M; Zagoya C; Mainz JG
    Front Immunol; 2022; 13():947359. PubMed ID: 36466839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry.
    Vongthilath R; Richaud Thiriez B; Dehillotte C; Lemonnier L; Guillien A; Degano B; Dalphin ML; Dalphin JC; Plésiat P
    PLoS One; 2019; 14(1):e0210201. PubMed ID: 30620748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
    Tesell MA; Alper CJ; Bacon R; Greenwood BC; Lenz K; Jeffrey PL; Stevens K
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1021-1025. PubMed ID: 31456498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
    Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
    [No Abstract]   [Full Text] [Related]  

  • 16. Rhinovirus Infection Is Associated With Airway Epithelial Cell Necrosis and Inflammation via Interleukin-1 in Young Children With Cystic Fibrosis.
    Montgomery ST; Frey DL; Mall MA; Stick SM; Kicic A;
    Front Immunol; 2020; 11():596. PubMed ID: 32328066
    [No Abstract]   [Full Text] [Related]  

  • 17. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.
    Sawicki GS; Van Brunt K; Booth J; Bailey E; Millar SJ; Konstan MW; Flume PA
    J Cyst Fibros; 2022 Jan; 21(1):96-103. PubMed ID: 34289939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis.
    Nayir Buyuksahin H; Yalçın E; Emiralioglu N; Hazırolan G; Ademhan Tural D; Ozsezen B; Sunman B; Guzelkas I; Dogru D; Ozcelik U; Kiper N
    Pediatr Int; 2022 Jan; 64(1):e15249. PubMed ID: 36321341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.
    Liou TG; Adler FR; Argel N; Asfour F; Brown PS; Chatfield BA; Daines CL; Durham D; Francis JA; Glover B; Heynekamp T; Hoidal JR; Jensen JL; Keogh R; Kopecky CM; Lechtzin N; Li Y; Lysinger J; Molina O; Nakamura C; Packer KA; Poch KR; Quittner AL; Radford P; Redway AJ; Sagel SD; Sprandel S; Taylor-Cousar JL; Vroom JB; Yoshikawa R; Clancy JP; Elborn JS; Olivier KN; Cox DR
    BMC Med Res Methodol; 2019 Apr; 19(1):88. PubMed ID: 31027503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.